Dr. Mark Basik

Academic title(s): 

Associate Professor of Surgery and Oncology

Dr. Mark Basik
Contact Information
Email address: 
mbasik [at] onc.jgh.mcgill.ca
Phone: 
(514) 340-8248
Location: 
Jewish General Hospital (JGH)
Division: 
General surgery and oncology
Hospital title: 
surgical oncologist
Clinical Interests: 

molecular genetics of breast and colon cancer

Biography: 

Dr. Basik is a surgical scientist at the Lady Davis Institute and an associate professor in the Departments of Surgery and Oncology at McGill University since 2003. He is the Head of the Cancer Genomics and Translational Research Laboratory and the Medical Director of the Inter-disciplinary Breast Cancer Team at the Segal cancer Center at the Jewish General Hospital. Dr. Basik’s laboratory is part of the FRQS Réseau de Cancer axe cancer du sein/ovaire, and as such actively participates in a province-wide breast tumor and plasma banking in breast cancer. His primary research interests are: the investigation of DNA changes in breast and colon cancer the study of mechanisms of resistance to different drugs used in breast and colon cancer, including chemotherapy and targeted therapies; the discovery and validation of tissue and plasma biomarkers predictive of response to treatment. Dr.Basik and his team are working in translational-cancer research, which aims at bridging basic and clinical research for the benefit of cancer patients. The strength of his laboratory is his easy access to clinical patient samples and use of cutting-edge technologies. 

To learn more about Dr. Basik's research visit the Cancer Genomics and Tranlastional Research Labratory.

Selected publications: 


1: Gotlieb R, Abitbol J, How JA, Ben-Brith I, Abenhaim HA, Lau SK, Basik M,
Rosberger Z, Geva N, Gotlieb WH, Mintz A. Gender differences in how physicians
access and process information. Gynecol Oncol Rep. 2019 Jan 2;27:50-53. doi:
10.1016/j.gore.2018.12.008. eCollection 2019 Feb. Review. PubMed PMID: 30662932;
PubMed Central PMCID: PMC6325067.


2: Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu
H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M,
Al Habyan S, Bijian K, Amant F, Witcher M, Behbod F, McCaffrey L, Alaoui-Jamali
MA, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH.
MNK1/NODAL signaling promotes invasive progression of breast ductal carcinoma in
situ. Cancer Res. 2019 Jan 18. pii: canres.1602.2018. doi:
10.1158/0008-5472.CAN-18-1602. [Epub ahead of print] PubMed PMID: 30659022.


3: Chennakrishnaiah S, Meehan B, D'Asti E, Montermini L, Lee TH, Karatzas N,
Buchanan M, Tawil N, Choi D, Divangahi M, Basik M, Rak J. Leukocytes as a
reservoir of circulating oncogenic DNA and regulatory targets of tumor-derived
extracellular vesicles. J Thromb Haemost. 2018 Sep;16(9):1800-1813. doi:
10.1111/jth.14222. Epub 2018 Aug 16. PubMed PMID: 29971917.


4: Hirukawa A, Smith HW, Zuo D, Dufour CR, Savage P, Bertos N, Johnson RM, Bui T,
Bourque G, Basik M, Giguère V, Park M, Muller WJ. Targeting EZH2 reactivates a
breast cancer subtype-specific anti-metastatic transcriptional program. Nat
Commun. 2018 Jun 29;9(1):2547. doi: 10.1038/s41467-018-04864-8. PubMed PMID:
29959321; PubMed Central PMCID: PMC6026192.


5: Mnatsakanyan R, Shema G, Basik M, Batist G, Borchers CH, Sickmann A, Zahedi
RP. Detecting post-translational modification signatures as potential biomarkers
in clinical mass spectrometry. Expert Rev Proteomics. 2018 Jun;15(6):515-535.
doi: 10.1080/14789450.2018.1483340. PubMed PMID: 29893147.


6: Goyette MA, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault MP, Johnson
RM, Carmeliet P, Basik M, Gaboury L, Muller WJ, Park M, Roux PP, Gratton JP, Côté
JF. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the
Metastatic Cascade during HER2-Positive Breast Cancer Progression. Cell Rep. 2018
May 1;23(5):1476-1490. doi: 10.1016/j.celrep.2018.04.019. PubMed PMID: 29719259.


7: Popp R, Basik M, Spatz A, Batist G, Zahedi RP, Borchers CH. How iMALDI can
improve clinical diagnostics. Analyst. 2018 May 15;143(10):2197-2203. doi:
10.1039/c8an00094h. Review. PubMed PMID: 29713694.


8: Daubriac J, Han S, Grahovac J, Smith E, Hosein A, Buchanan M, Basik M, Boucher
Y. The crosstalk between breast carcinoma-associated fibroblasts and cancer cells
promotes RhoA-dependent invasion via IGF-1 and PAI-1. Oncotarget. 2017 Dec
28;9(12):10375-10387. doi: 10.18632/oncotarget.23735. eCollection 2018 Feb 13.
PubMed PMID: 29535813; PubMed Central PMCID: PMC5828213.


9: Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, Zuo D, Liu
L, Bertos NR, Munoz-Ramos V, Basik M, Petrecca K, Asselah J, Meterissian S, Guiot
MC, Omeroglu A, Kleinman CL, Park M, Ragoussis J. A Targetable EGFR-Dependent
Tumor-Initiating Program in Breast Cancer. Cell Rep. 2017 Oct 31;21(5):1140-1149.
doi: 10.1016/j.celrep.2017.10.015. PubMed PMID: 29091754.


10: Légaré S, Chabot C, Basik M. SPEN, a new player in primary cilia formation
and cell migration in breast cancer. Breast Cancer Res. 2017 Sep 6;19(1):104.
doi: 10.1186/s13058-017-0897-3. PubMed PMID: 28877752; PubMed Central PMCID:
PMC5588740.

 

View more

Back to top